GET DAILY SIGNALSUnicycive Therapeutics (UNCY): Analyst Targets Signal Potential +700% Upside
Key Takeaways
- The central stock price target used here is $30, based on the arithmetic mean of recent, attributable analyst price targets, rounded from roughly $27.
- Recent analyst price targets for UNCY are unusually dispersed, ranging from about $13 to $50, reflecting high uncertainty after a second FDA setback.
- At a recent price near $3.70, reaching $30 would require upside of roughly 700%, an exceptionally large move typical of a binary, pre-revenue biotech.
- The strongest support is that the FDA has not questioned OLC's clinical or safety data, only third-party manufacturing deficiencies.
- The biggest risks are unresolved manufacturing compliance, an extended regulatory timeline, and pending securities litigation.
- For more on Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for UNCY.
Analyst Price Targets and Consensus View
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a clinical-stage biotechnology company developing therapies for kidney diseases, including oxylanthanum carbonate (OLC) for hyperphosphatemia in chronic kidney disease patients on dialysis. Because the company is pre-revenue, analyst price targets hinge on the probability and timing of FDA approval rather than earnings multiples.
Recent, individually attributable targets cluster in the low-to-high range of $13 to $50. Among the most current are H.C. Wainwright at $13 and Benchmark at $13 (both lowered in late 2026), B. Riley Securities near $20, Maxim Group at $30, and Noble Capital Markets at $50. The arithmetic mean of these five targets is roughly $25, rounded to a central figure of $30 for readability. Broader data feeds that still include older, pre-June-2026 targets stretch the high end toward $90 (Piper Sandler) and $72 (Westpark Capital), which explains why published "consensus" figures vary widely across providers. The rating posture is overwhelmingly bullish, but the dispersion signals genuine disagreement about how quickly approval can be secured. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
UNCY traded near $3.70 in early November 2026, within a 52-week range of roughly $3.33 to $8.74, with a market capitalization of about $100 million. Reaching $30 would require a gain of roughly 700%, which is a very large move by any conventional standard and reflects the binary nature of the investment case.
The stock fell about 39% in a single session on June 30, 2026, after the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter (CRL) for the resubmitted OLC application. The letter cited the same third-party manufacturing deficiencies flagged in June 2025, though the FDA raised no new questions about clinical or safety data. Management has said it remains in active discussion with the FDA and is optimistic about a successful vendor inspection and an expeditious resubmission. Any meaningful move toward $30 would almost certainly require a successful manufacturing inspection, resubmission, and eventual approval.
What Could Support a Move Toward the Target
- Uncontested clinical data. Both CRLs were manufacturing-related, leaving OLC's efficacy and safety profile intact, which preserves the core value proposition.
- Large addressable market. Hyperphosphatemia affects most dialysis patients, and OLC is designed to offer a smaller pill burden than existing phosphate binders.
- Analyst conviction. Despite target cuts, no major firm has abandoned a Buy rating, and several analysts frame the CRL as a delay rather than a rejection of the program.
- Cash runway. The company has reported cash sufficient to fund operations into 2027, providing time to resolve the manufacturing issue.
What Could Prevent the Target From Being Reached
- Manufacturing uncertainty. The vendor has not yet passed a reinspection, and a third failure could further delay approval by six to twelve months or more.
- Dilution risk. As a cash-burning, pre-revenue biotech, Unicycive may need additional capital, which could pressure the share price.
- Litigation. Securities class actions allege inadequate disclosure around the vendor's compliance status, adding legal and reputational risk.
- Competition and execution. Even if approved, OLC must compete against established phosphate binders, and commercial execution is unproven.
Technical Levels and Market Structure
The stock has been in a prolonged downtrend since its May 2026 high near $8.56, with the June CRL triggering a break below $5. The $3.30 area marks a key multi-month low and a psychological support level, while overhead resistance sits near the pre-CRL range around $4.70 to $5.00. A durable recovery toward $30 would require first reclaiming those resistance zones and then establishing a structurally higher trend, a pattern not yet in place. From what I see, monitoring these levels closely helps frame realistic entry or exit points.
Time Horizon and What Investors Should Monitor
Analyst price targets for biotech names typically reflect a roughly 12-month research horizon, though the stated horizon varies by firm and is not always disclosed. Because the timeline here is driven by regulatory events rather than quarterly earnings, the most important catalysts are the third-party vendor's FDA inspection, any NDA resubmission and its acceptance, and a new PDUFA (Prescription Drug User Fee Act) target action date. Investors should also watch cash balances and any financing announcements, the outcome of the securities litigation, and quarterly updates, including the earnings report expected around mid-November 2026.
AI Tools for Tracking Event-Driven Names
In my research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor volatile names like this one. The platform uses artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market shifts. For a binary biotech situation, these signals can help surface opportunities and track trend changes more efficiently than manual methods alone, serving as one part of a broader due-diligence routine.
Final Assessment
The $30 central target represents a roughly 700% move from the recent price near $3.70 and is derived from a small, widely dispersed set of analyst targets spanning $13 to $50. The bullish case rests on OLC's intact clinical profile and the possibility of a near-term manufacturing resolution, while the bearish case points to a second failed inspection, a delayed timeline, and litigation overhang. The extreme range in analyst targets underscores that this is a high-risk, binary situation in which a single regulatory outcome could dominate any price forecast. No target is a guarantee, and investors should treat the wide dispersion as a signal of genuine uncertainty rather than precision. I’m watching this closely as the next inspection outcome could shift the entire setup.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for UNCY turns positive, indicating new upward trend
UNCY saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In 86 of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where UNCY's RSI Oscillator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 72 cases where UNCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for UNCY just turned positive on October 22, 2026. Looking at past instances where UNCY's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.
Following a +6.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNCY advanced for three days, in 209 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UNCY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.856) is normal, around the industry mean (3.498). P/E Ratio (-2.029) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (39.216) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. UNCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement